Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.48
HZNP's Cash-to-Debt is ranked lower than
72% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. HZNP: 0.48 )
Ranked among companies with meaningful Cash-to-Debt only.
HZNP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.92 Max: N/A
Current: 0.48
Equity-to-Asset 0.41
HZNP's Equity-to-Asset is ranked lower than
78% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. HZNP: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
HZNP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.45 Max: 0.7
Current: 0.41
-0.77
0.7
Interest Coverage 0.27
HZNP's Interest Coverage is ranked lower than
99% of the 646 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. HZNP: 0.27 )
Ranked among companies with meaningful Interest Coverage only.
HZNP' s Interest Coverage Range Over the Past 10 Years
Min: 0.27  Med: 0.79 Max: 0.79
Current: 0.27
0.27
0.79
Piotroski F-Score: 5
Altman Z-Score: 1.02
Beneish M-Score: -2.44
WACC vs ROIC
9.89%
-3.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 2.29
HZNP's Operating Margin % is ranked lower than
69% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.38 vs. HZNP: 2.29 )
Ranked among companies with meaningful Operating Margin % only.
HZNP' s Operating Margin % Range Over the Past 10 Years
Min: -1841.5  Med: -238.23 Max: 7.31
Current: 2.29
-1841.5
7.31
Net Margin % -1.34
HZNP's Net Margin % is ranked lower than
76% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. HZNP: -1.34 )
Ranked among companies with meaningful Net Margin % only.
HZNP' s Net Margin % Range Over the Past 10 Years
Min: -1635.12  Med: -333.61 Max: 5.22
Current: -1.34
-1635.12
5.22
ROE % -0.94
HZNP's ROE % is ranked lower than
74% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.12 vs. HZNP: -0.94 )
Ranked among companies with meaningful ROE % only.
HZNP' s ROE % Range Over the Past 10 Years
Min: -523.78  Med: -111.48 Max: 4.27
Current: -0.94
-523.78
4.27
ROA % -0.39
HZNP's ROA % is ranked lower than
72% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. HZNP: -0.39 )
Ranked among companies with meaningful ROA % only.
HZNP' s ROA % Range Over the Past 10 Years
Min: -186.55  Med: -63.12 Max: 1.89
Current: -0.39
-186.55
1.89
ROC (Joel Greenblatt) % 43.17
HZNP's ROC (Joel Greenblatt) % is ranked higher than
79% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.08 vs. HZNP: 43.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HZNP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7948.82  Med: -2664.68 Max: 520.88
Current: 43.17
-7948.82
520.88
3-Year Revenue Growth Rate 115.50
HZNP's 3-Year Revenue Growth Rate is ranked higher than
98% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. HZNP: 115.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HZNP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.5 Max: 115.5
Current: 115.5
0
115.5
GuruFocus has detected 4 Warning Signs with Horizon Pharma PLC $HZNP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HZNP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

HZNP Guru Trades in Q1 2016

Steven Cohen 1,019,400 sh (New)
Ken Heebner 330,000 sh (+60.98%)
Paul Tudor Jones 72,983 sh (+50.26%)
Julian Robertson 868,477 sh (+5.45%)
Jim Simons Sold Out
Steve Mandel 13,997,232 sh (-10.28%)
RS Investment Management 1,453,024 sh (-34.27%)
Joel Greenblatt 1,053,933 sh (-49.21%)
» More
Q2 2016

HZNP Guru Trades in Q2 2016

Julian Robertson 894,577 sh (+3.01%)
RS Investment Management Sold Out
Ken Heebner Sold Out
Joel Greenblatt Sold Out
Steve Mandel Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 359,800 sh (-64.70%)
» More
Q3 2016

HZNP Guru Trades in Q3 2016

Paul Tudor Jones 49,605 sh (New)
Ken Heebner 1,000,000 sh (New)
Steven Cohen 509,400 sh (+41.58%)
Julian Robertson 673,933 sh (-24.66%)
» More
Q4 2016

HZNP Guru Trades in Q4 2016

Joel Greenblatt 126,466 sh (New)
Paul Tudor Jones 104,075 sh (+109.81%)
Ken Heebner 1,530,000 sh (+53.00%)
Julian Robertson 793,933 sh (+17.81%)
Steven Cohen 572,900 sh (+12.47%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:ENDP, NAS:AKRX, NAS:IRWD, NAS:MDCO, NAS:NBIX, NAS:RDUS, OTCPK:STDAF, NAS:PCRX, NAS:SUPN, NAS:EGRX, NAS:MNTA, NAS:IPXL, OTCPK:EVTCY, NAS:DEPO, NAS:SGYP, OTCPK:TWMJF, NAS:OPK, NYSE:PTHN, OTCPK:NPPNY, NYSE:LCI » details
Traded in other countries:HPR.Germany,
Horizon Pharma PLC is a specialty pharmaceutical company. The Company's product portfolio consists of ACTIMMUNE, DUEXIS, PENNSAID 2% and RAYOS/LODOTRA, which addresses the unmet therapeutic needs in arthritis, pain, inflammatory and/or orphan diseases.

Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.

Ratios

vs
industry
vs
history
Forward PE Ratio 3.95
HZNP's Forward PE Ratio is ranked higher than
97% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.82 vs. HZNP: 3.95 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 43.81
HZNP's Price-to-Owner-Earnings is ranked lower than
66% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.27 vs. HZNP: 43.81 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HZNP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.47  Med: 44.55 Max: 85.12
Current: 43.81
21.47
85.12
PB Ratio 1.92
HZNP's PB Ratio is ranked higher than
63% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. HZNP: 1.92 )
Ranked among companies with meaningful PB Ratio only.
HZNP' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 2.24 Max: 14.94
Current: 1.92
0.8
14.94
PS Ratio 2.85
HZNP's PS Ratio is ranked lower than
54% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. HZNP: 2.85 )
Ranked among companies with meaningful PS Ratio only.
HZNP' s PS Ratio Range Over the Past 10 Years
Min: 1.34  Med: 4.05 Max: 12.65
Current: 2.85
1.34
12.65
Price-to-Free-Cash-Flow 7.42
HZNP's Price-to-Free-Cash-Flow is ranked higher than
88% of the 185 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.92 vs. HZNP: 7.42 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HZNP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.79  Med: 14.21 Max: 499.62
Current: 7.42
6.79
499.62
Price-to-Operating-Cash-Flow 7.06
HZNP's Price-to-Operating-Cash-Flow is ranked higher than
83% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.34 vs. HZNP: 7.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HZNP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.47  Med: 13.53 Max: 223.97
Current: 7.06
6.47
223.97
EV-to-EBIT 152.71
HZNP's EV-to-EBIT is ranked lower than
97% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.61 vs. HZNP: 152.71 )
Ranked among companies with meaningful EV-to-EBIT only.
HZNP' s EV-to-EBIT Range Over the Past 10 Years
Min: -775.4  Med: -1.5 Max: 219.8
Current: 152.71
-775.4
219.8
EV-to-EBITDA 14.59
HZNP's EV-to-EBITDA is ranked higher than
53% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.32 vs. HZNP: 14.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
HZNP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -608  Med: -0.3 Max: 518
Current: 14.59
-608
518
Current Ratio 2.01
HZNP's Current Ratio is ranked lower than
55% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. HZNP: 2.01 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 2 Max: 4.39
Current: 2.01
0.16
4.39
Quick Ratio 1.72
HZNP's Quick Ratio is ranked higher than
50% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. HZNP: 1.72 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.79 Max: 4.27
Current: 1.72
0.16
4.27
Days Inventory 130.07
HZNP's Days Inventory is ranked lower than
56% of the 567 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.74 vs. HZNP: 130.07 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s Days Inventory Range Over the Past 10 Years
Min: 13.1  Med: 48.48 Max: 184.95
Current: 130.07
13.1
184.95
Days Sales Outstanding 144.71
HZNP's Days Sales Outstanding is ranked lower than
85% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. HZNP: 144.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.08  Med: 89.59 Max: 144.71
Current: 144.71
67.08
144.71
Days Payable 77.07
HZNP's Days Payable is ranked higher than
54% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. HZNP: 77.07 )
Ranked among companies with meaningful Days Payable only.
HZNP' s Days Payable Range Over the Past 10 Years
Min: 27.59  Med: 199.62 Max: 410.36
Current: 77.07
27.59
410.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -37.30
HZNP's 3-Year Average Share Buyback Ratio is ranked lower than
91% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. HZNP: -37.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HZNP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -428.1  Med: -84.9 Max: 0
Current: -37.3
-428.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.54
HZNP's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
66% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.61 vs. HZNP: 1.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HZNP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.5  Med: 3.73 Max: 29.51
Current: 1.54
1.5
29.51
Price-to-Median-PS-Value 0.70
HZNP's Price-to-Median-PS-Value is ranked higher than
85% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.22 vs. HZNP: 0.70 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HZNP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.39  Med: 1.04 Max: 2.79
Current: 0.7
0.39
2.79
Earnings Yield (Greenblatt) % 0.64
HZNP's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 611 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. HZNP: 0.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HZNP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 0.7 Max: 2.6
Current: 0.64
0.5
2.6

More Statistics

Revenue (TTM) (Mil) $915.3
EPS (TTM) $ -0.08
Beta1.44
Short Percentage of Float10.28%
52-Week Range $13.05 - 23.44
Shares Outstanding (Mil)162.33

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,046 1,329 1,463
EPS ($) 2.00 4.17 2.90
EPS without NRI ($) 2.00 4.17 2.90
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
Julian Robertson Sells Delta Air Lines, Alphabet Dec 07 2016 
Julian Robertson Buys 8 New Stakes in 4th Quarter Mar 09 2016 
Sheets Smith Wealth Management Buys Companies With no Debts Sep 01 2015 
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 

More From Other Websites
Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 1, 2017 Mar 01 2017
Horizon Pharma Plc :HZNP-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017 Feb 28 2017
Horizon (HZNP) Misses on Earnings in Q4, View Disappoints Feb 28 2017
Horizon Pharma plc Launches RAREis™ Campaign Elevating Faces of the Rare Disease Community Feb 28 2017
Horizon Pharma Dips On 2017 View Despite 'Nothing Alarming' In Q4 Feb 27 2017
Edited Transcript of HZNP earnings conference call or presentation 27-Feb-17 1:00pm GMT Feb 27 2017
Horizon Pharma (HZNP) Misses Q4 Earnings & Revenues Feb 27 2017
Horizon Pharma reports 4Q loss Feb 27 2017
Horizon Pharma reports 4Q loss Feb 27 2017
7:09 am Horizon Pharma beats by $0.13, reports revs in-line; guides Q1 revs in-line; guides Q2 (Jun)... Feb 27 2017
HORIZON PHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Change in... Feb 27 2017
Q4 2016 Horizon Pharma PLC Earnings Release - Before Market Open Feb 27 2017
Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides... Feb 27 2017
Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint? Feb 23 2017
Horizon Pharma Plc – Value Analysis (NASDAQ:HZNP) : February 14, 2017 Feb 14 2017
Horizon Pharma plc to Participate in Cowen and Company 37th Annual Health Care Conference Feb 14 2017
Horizon Pharma plc to Host Fourth-Quarter 2016 Conference Call and Webcast on February 27, 2017 Jan 27 2017
Horizon Pharma Plc breached its 50 day moving average in a Bullish Manner : HZNP-US : January 11,... Jan 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)